ARS Pharmaceuticals annual stock-based compensation
2020
2021
2022
2023
2024
2025
ARS Pharmaceuticals Stock-Based Compensation Growth & History (SPRY)
ARS Pharmaceuticals's stock-based compensation was $22.1M for fiscal 2025.
View full ARS Pharmaceuticals company overviewARS Pharmaceuticals annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $22.1M | $7.6M | +52.02% |
| 2024 | 2024-12-31 | $14.5M | $5.3M | +57.38% |
| 2023 | 2023-12-31 | $9.2M | $3.4M | +58.05% |
| 2022 | 2022-12-31 | $5.8M | $3.0M | +106.54% |
| 2021 | 2021-12-31 | $2.8M | $189,000 | +7.16% |
| 2020 | 2020-12-31 | $2.6M | — | — |
ARS Pharmaceuticals quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $12.4M | $7.0M | +130.78% |
| Q1 2026 | 2026-03-31 | $7.4M | $2.1M | +40.11% |
| Q4 2025 | 2025-12-31 | $5.7M | $1.5M | +34.58% |
| Q3 2025 | 2025-09-30 | $5.7M | $2.1M | +58.42% |
| Q2 2025 | 2025-06-30 | $5.4M | $2.0M | +59.61% |
| Q1 2025 | 2025-03-31 | $5.3M | $2.0M | +59.82% |
| Q4 2024 | 2024-12-31 | $4.3M | $2.0M | +87.14% |
| Q3 2024 | 2024-09-30 | $3.6M | $982,000 | +37.64% |
| Q2 2024 | 2024-06-30 | $3.4M | $1.3M | +60.39% |
| Q1 2024 | 2024-03-31 | $3.3M | $1.1M | +47.33% |
| Q4 2023 | 2023-12-31 | $2.3M | −$2.5M | −52.17% |
| Q3 2023 | 2023-09-30 | $2.6M | $2.1M | +467.17% |
| Q2 2023 | 2023-06-30 | $2.1M | $1.7M | +489.33% |
| Q1 2023 | 2023-03-31 | $2.3M | $2.0M | +752.27% |
| Q4 2022 | 2022-12-31 | $4.8M | — | — |
| Q3 2022 | 2022-09-30 | $460,000 | −$4.6M | −90.83% |
| Q2 2022 | 2022-06-30 | $356,000 | −$4.4M | −92.47% |
| Q1 2022 | 2022-03-31 | $264,000 | −$4.0M | −93.84% |
| Q3 2021 | 2021-09-30 | $5.0M | $4.8M | +2527.75% |
| Q2 2021 | 2021-06-30 | $4.7M | $4.6M | +3595.31% |
| Q1 2021 | 2021-03-31 | $4.3M | $4.2M | +9017.02% |
| Q4 2020 | 2020-12-31 | $2.3M | — | — |
| Q3 2020 | 2020-09-30 | $191,000 | — | — |
| Q2 2020 | 2020-06-30 | $128,000 | — | — |
| Q1 2020 | 2020-03-31 | $47,000 | — | — |
ARS Pharmaceuticals stock-based compensation trends
Over the last five fiscal years, ARS Pharmaceuticals's stock-based compensation increased from $2.6M to $22.1M, a change of $19.5M. The latest reported quarter, Q2 2026, shows $12.4M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review ARS Pharmaceuticals source filings ↗